Schmitz Uli, Tan Seng-Lai
Genelabs Technologies, Inc., 505 Penobscot Drive, Redwood City, CA 94063, USA.
Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):77-92. doi: 10.2174/157489108784746597.
The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
丙型肝炎病毒（HCV）非结构5A（NS5A）蛋白对于病毒RNA复制至关重要，并且可能在颠覆宿主细胞内信号通路中发挥作用。尽管尚未赋予NS5A内在酶活性，但这种富含脯氨酸的亲水性磷蛋白可能通过与病毒和细胞因子相互作用来发挥其功能。最近使用HCV复制子细胞培养系统作为HCV RNA复制模型以及用于高通量筛选药理抑制剂的研究表明，阻断NS5A是治疗HCV的一种有前景的治疗策略。本综述将总结我们在理解NS5A在HCV RNA复制中的作用方面取得的进展，并将介绍关于NS5A抑制剂的最新专利。
